ClinicalTrials.gg
CompletedNCT03396250Updated Mar 20, 2019

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

A Phase 1 interventional study of Naproxen sodium and diphenhydramine hydrochloride soft capsules and Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111) in Pain, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-20.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Pain by Bayer — none open to participants now, none under way, none of them phase 3. Pain · Bayer.

Enrollment
10th of 14
36 · median 113
Started
2018
the only one that year
Phase 1
8 of 14
none open now
Registered
10th of 14
by date

Among the 14 studies in Pain by Bayer, this one is the 10th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 1, and was the 10th registered.

Pain

10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 14 studies in Pain by Bayer is open now. The open studies under Pain, anywhere →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Pain by Bayer as a file.
02

Study summary

To evaluate the relative bioavailability of Naproxen Sodium 220 mg and diphenhydramine hydrochloride (DPH HCL) 25 mg soft capsules (Test) versus Naproxen Sodium 220 mg and diphenhydramine hydrochloride 25 mg tablets (Reference) after a single oral administration under fasted condition in healthy adults subjects.

To assess the safety and tolerability of the investigational products in terms of advent events (AEs) and clinical parameters.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult men or women
  • Age 18 to 55 years inclusive;
  • 18.5 to 30.0 kg/m2 inclusive

Exclusion criteria

Exclusion Criteria:

  • History of symptoms with the use of naproxen/naproxen sodium, diphenhydramine hydrochloride/citrate, acetylsalicylic acid, other Nonsteroidal anti-inflammatory drugs (NSAIDs) or similar pharmacological agents or components of the products;
  • Females who are pregnant or lactating;
  • Vegetarian or restricted diet (e.g., gluten-free);
  • Any active disease, acute or chronic;
  • Have taken naproxen/naproxen sodium, DPH HCl or diphenhydramine citrate, DPH HCl or diphenhydramine citrate-containing products, acetylsalicylic acid (ASA), ASA-containing products, acetaminophen, ibuprofen, any other NSAID (Over-the -counter [OTC] or prescription) or NSAID containing products, xanthines, antihistamines or caffeine-containing products (e.g. coffee, tea and chocolate) 7 days prior to dosing or during the Dosing Periods, other than trial treatment;
  • Use of any over-the-counter or prescription medications, vitamins or herbal supplements (except acceptable forms of ) within 7 days prior to dosing or throughout the trial, unless in the opinion of the Investigator, the medication will not interfere with the trial procedures, data integrity, or compromise the safety of the subject;
  • Positive test for (HIV) antibodies and antigens;
  • Positive test for surface antigen (HBsAg) test;
  • Positive test for anti- virus (Anti-HCV) antibodies;
  • In the judgment of the investigator, any need of other medication during the trial besides the test and reference study medication;
  • Recently had (past 30 days) or plan to have surgery, an invasive procedure, tattoos or piercings during the trial or within 2 weeks after treatment;
  • More than moderate alcohol consumption (>40 g of alcohol regularly per day);
  • Positive alcohol or drug screen at Screening or on Day -1 of each dosing period.
  • Any history or suspicion of barbiturate, amphetamine, benzodiazepine, cocaine, opiates, methamphetamine or cannabis abuse;
  • Loss of blood in excess of 50 mL to 499 mL within 30 days or 500 ml within 56 days of the first dose of trial treatment (e.g., donation, plasmapheresis or injury);
  • Excessive sports or sauna within 5 days before start of the treatment phase and unwilling to abstain during the trial;
  • Have a count \<150,000/mm3 and in the judgment of the investigator, presents a significant bleeding risk;
  • History of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding);
  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases (including glaucoma or benign prostatic hypertrophy) or or any other disease or condition which could influence the metabolism of the drug;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Test product + Reference product

    Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.

    Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules · Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)

  • Experimental
    Reference product + Test product

    Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.

    Drug: Naproxen sodium and diphenhydramine hydrochloride soft capsules · Drug: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)

Interventions

  • DrugNaproxen sodium and diphenhydramine hydrochloride soft capsules

    Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)

  • DrugNaproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)

    Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)

06

What researchers measure

Primary outcomes

  1. AUC

    Area under the concentration vs. time curve from zero to infinity after single (first) dose

    Time frame: Within 30 minutes prior to dosing (baseline) 10, 20, 30, 45, 60 minutes and 1 hour 20 minutes, 1 hour 40 minutes, 2, 2 hours 30 minutes, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose

  2. AUC(0-tlast)

    Area under plasma concentration vs. time curve from zero to last data point \>LLOQ (lower limit of quantitation), calculated up by linear trapezoidal rule, down by logarithmic trapezoidal rule

    Time frame: Within 30 minutes prior to dosing (baseline) 10, 20, 30, 45, 60 minutes and 1 hour 20 minutes, 1 hour 40 minutes, 2, 2 hours 30 minutes, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose

  3. Cmax

    Maximum observed drug concentration, directly observed from analytical data

    Time frame: Within 30 minutes prior to dosing (baseline) 10, 20, 30, 45, 60 minutes and 1 hour 20 minutes, 1 hour 40 minutes, 2, 2 hours 30 minutes, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hours post-dose

Secondary outcomes

  1. Number of adverse events as a measure of safety and tolerability

    Time frame: Up to 5 weeks

07

Study locations

1 site
  • ICON Development Solutions, LLC
    San Antonio, Texas 78219, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Mar 2018, 1 month.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 1 month is below that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2018
First posted
Jan 10, 2018
StartActual
Feb 12, 2018
Primary completionActual
Mar 26, 2018
CompletionActual
Mar 29, 2018
Last update
Mar 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03396250
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 10, 2018
Start date
Feb 12, 2018
Primary completion
Mar 26, 2018
Completion
Mar 29, 2018
Last update
Mar 20, 2019

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion